Selda Samakoglu
Bristol-Myers Squibb
7 Papers
2 Citations
Selda Samakoglu is an academic researcher from Bristol-Myers Squibb. The author has contributed to research in topics: Durvalumab & Ibrutinib. The author has an hindex of 3, co-authored 4 publications.
Chat about Author
Papers
Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study
Stephen M. Ansell,Monique C. Minnema,Peter Johnson,John M. Timmerman,Philippe Armand,Margaret A. Shipp,Scott J. Rodig,Scott J. Rodig,Azra H. Ligon,Margaretha G.M. Roemer,Nishitha Reddy,Jonathon B. Cohen,Sarit Assouline,Michelle Poon,Manish Sharma,Kazunobu Kato,Selda Samakoglu,Anne Sumbul,Andrew Grigg +18 more
TL;DR: Nivolumab monotherapy is associated with a favorable safety profile but a low overall response rate among patients with DLBCL who are ineligible for autologous hematopoietic cell transplantation or who experienced failure with auto-HCT.
315
A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors
David S. Hong,Drew W. Rasco,Michael H. Veeder,Jason J. Luke,Jason C. Chandler,Ani Sarkis Balmanoukian,Thomas J. George,Pamela N. Munster,Jordan Berlin,Martin Gutierrez,Alain C. Mita,Heather A. Wakelee,Selda Samakoglu,Shanhong Guan,Isaiah W. Dimery,Thorsten Graef,Erkut Borazanci +16 more
TL;DR: The combination of ibrutinib 560 mg daily and durvalumab 10 mg/kg every 2 weeks had an acceptable safety profile and antitumor activity was limited in the study population of patients with relapsed/refractory solid tumors.
Abstract CT130: Trial in progress: A phase 2 multicenter study (IOV-LUN-202) of autologous tumor-infiltrating lymphocyte (TIL) cell therapy (LN-145) in patients with metastatic non-small cell lung cancer (mNSCLC)
Jason Chesney,Adam J. Schoenfeld,Trisha Wise-Draper,Ammar Sukari,Kai He,Friedrich Graf Finckenstein,Parameswaran Hari,Madan Jagasia,Selda Samakoglu,A. Leighton-Swayze,Guang Chen,Y. K. Hong +11 more
TL;DR: The ongoing IOV-LUN-202 study is amended, evaluating LN-145 in patients with stage IV mNSCLC after confirmed disease progression on front-line standard-of-care treatment, including concurrent or sequential ICI + chemotherapy ± bevacizumab.
2
EP08.01-110 Trial in Progress: A Phase 2 Multicenter Study (IOV-LUN-202) of Autologous Tumor-infiltrating Lymphocyte (TIL) Cell Therapy (LN-145) in mNSCLC
Jason Chesney,Adam J. Schoenfeld,Trisha Wise-Draper,Ammar Sukari,Kewu He,F. Graf Finckenstein,Parameswaran Hari,Madan Jagasia,Selda Samakoglu,A. Leighton-Swayze,G. Chen,Yong-Kil Hong +11 more
TL;DR: Schoenfeld et al. as mentioned in this paper proposed LN-145, an autologous TIL cell therapy, which demonstrated feasibility, safety, and an early signal of efficacy with a 21.4% objective response rate (ORR) in heavily pretreated patients with mNSCLC, including responders with PD-L1-negative tumors.
Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma
Philippe Armand,Ann Janssens,Giuseppe Gritti,John Radford,John Radford,John M. Timmerman,Antonio Pinto,Santiago Mercadal Vilchez,P. Johnson,David Cunningham,John P. Leonard,John P. Leonard,Scott J. Rodig,Scott J. Rodig,Patricia Martin-Regueira,Anne Sumbul,Selda Samakoglu,Hao Tang,Stephen M. Ansell +18 more
TL;DR: In conclusion, nivolumab monotherapy was associated with very limited activity in patients with R/R FL and better understanding of the immune biology of this disease may facilitate the development of effective checkpoint-based strategies.